Artículos por temáticas

The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation

Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R.

Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003.

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease

Herrmann N, Gauthier S, Boneva N, Lemming OM; 10158 Investigators.

Int Psychogeriatr. 2013 Jun;25(6):919-27. doi: 10.1017/S1041610213000239. Epub 2013 Mar 8.

The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease

Lewis JE, McDaniel HR, Agronin ME, Loewenstein DA, Riveros J, Mestre R, Martinez M, Colina N, Abreu D, Konefal J, Woolger JM, Ali KH.

J Alzheimers Dis. 2013;33(2):393-406. doi: 10.3233/JAD-2012-121381.

Trafficking in neurons: searching for new targets for Alzheimer's disease future therapies

Musardo S, Saraceno C, Pelucchi S, Marcello E.

Eur J Pharmacol. 2013 Nov 5;719(1-3):84-106. doi: 10.1016/j.ejphar.2013.07.019. Epub 2013 Jul 23.

Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?

Corbett A, Ballard C.

Expert Opin Investig Drugs. 2013 Aug;22(8):941-3. doi: 10.1517/13543784.2013.815723. Epub 2013 Jul 1.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6.

A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse)

Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

Mol Neurobiol. 2013 Apr;47(2):711-25. doi: 10.1007/s12035-012-8375-5. Epub 2012 Nov 14.

Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment

Grill JD, Karlawish J, Elashoff D, Vickrey BG.

Alzheimers Dement. 2013 May;9(3):356-359.e1. doi: 10.1016/j.jalz.2012.03.001. Epub 2012 Nov 8.

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data

Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SA.

Eur J Clin Pharmacol. 2013 Jun;69(6):1247-60. doi: 10.1007/s00228-012-1459-3. Epub 2013 Jan 4.

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S.

Br J Clin Pharmacol. 2013 May;75(5):1299-311. doi: 10.1111/j.1365-2125.2012.04472.x.

MR imaging features of amyloid-related imaging abnormalities

Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M.

AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub 2013 Apr 11.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S.

J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.

Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study

Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC; Ginkgo Evaluation of Memory (GEM) Study Investigators.

Neurology. 2013 Sep 3;81(10):896-903. doi: 10.1212/WNL.0b013e3182a35228. Epub 2013 Aug 2.

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, F

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.

Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database

Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R.

J Alzheimers Dis. 2013;37(1):173-83. doi: 10.3233/JAD-130575.